Jiangsu Hengrui Medicine
600276.SS
#504
Rank
NZ$71.01 B
Marketcap
$11.13
Share price
0.19%
Change (1 day)
7.52%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2023 (TTM): $0.15

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is $0.16. In 2022 the company made an earnings per share (EPS) of $0.16 a decrease over its 2021 EPS that were of $0.19.

EPS history for Jiangsu Hengrui Medicine from 2002 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.15-5.27%
2022$0.16-17.1%
2021$0.19-24.44%
2020$0.2520.3%
2019$0.2125.58%
2018$0.1727.55%
2017$0.1321.64%
2016$0.1113.57%
2015$0.0946039.86%
2014$0.0676421.33%
2013$0.0557417.7%
2012$0.0473625.56%
2011$0.0377226.22%
2010$0.0298810.3%
2009$0.0270957.92%
2008$0.0171611.06%
2007$0.0154585.81%
2006$0.00831487.94%
2005$0.00442433.97%
2004$0.00330229.78%
2003$0.00254419.78%
2002$0.002124